Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC ...Middle East

CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for...

Hence then, the article about kelun biotech s new drug application for its novel next generation selective ret inhibitor a400 ep0031 accepted for review by the nmpa for the treatment of ret fusion positive nsclc was published today ( Tuesday 23/09/2025 - 05:26 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC )

Also on site :

• Wharton’s great contrarian says AI adoption isn’t an easy way to cut headcount: ‘The key thing … is just how much work is involved in doing it’
• Ex-husband charged in deaths of Monique and Spencer Tepe
• A Red State’s High Court Gave Sam Alito the Dobbs Rejoinder He Deserves